10月23日，Iovance Biotherapeutics盘中下跌5.13%，报13.8美元/股，成交额6616.5万美元。
近几日公司消息面主要集中于ESMO大会展示其跨实体瘤TIL细胞治疗平台，重点包括一线黑色素瘤及既往经治非小细胞肺癌中的深度、持久缓解数据。
此前公司还在9月底将全年营收指引上调至4.10亿至4.20亿美元，高于原先的3.50亿至3.70亿美元，反映Amtagvi与Proleukin需求改善。此次股价走弱，发生在前期利好披露之后。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.